WHO Report Highlights Gender Disparities, Cites AIDS As Leading Cause Of Women’s Deaths

Women around the world are “denied a chance to develop their full human potential” because of a lack of essential health care throughout their lives, according to a World Health Organization report released Monday, Reuters reports.

Non-Invasive Uterine Fibroid Treatment With ExAblate(R) Shows Significantly Fewer Complications And Faster Recovery Than Hysterectomy

InSightec Ltd. announced that three new papers published in the November issue of Ultrasound in Obstetrics and Gynecology add to the growing body of data supporting the use of ExAblate(R) as a safe, effective and durable treatment for uterine fibroids.

Hard Training Reduced Fertility

Are you a female athlete or just someone who likes challenging workouts — who also wants to get pregnant? It may make sense to ease off a bit as you try to get pregnant. New research from the Norwegian University of Science and Technology (NTNU) shows that the body may not have enough energy to [...]

Boston Scientific’s Urology/Gynecology Products Featured In Studies At Global Congress

Boston Scientific Corporation (NYSE: BSX) announced its schedule of events at the 38th annual Global Congress for Minimally Invasive Gynecology (AAGL), which runs from November 15-19 in Orlando, Florida.

BJOG Release: Study Raises Concerns About Cosmetic Labial Surgery

New research to be published in BJOG: An International Journal of Obstetrics and Gynaecology reviews the available literature on cosmetic labial surgery and underlines the striking lack of evidence on the safety and long-term consequences of such procedures. The authors caution that medically nonessential surgery to the labia is being promoted to women, while no [...]

Bisphenol-A Linked to Male Sexual Dysfunction (CME/CE)

Bisphenol-A (BPA) hardens plastic but appears to be associated with the opposite effect in men.

FDA Begins to Shape Rules for Online Drug, Device Ads

WASHINGTON (MedPage Today) — Drug and device companies are urging the FDA to establish clear guidelines that can allow the industry to discuss and promote their products in the murky world of online social media.

Axelar AB to present data from ongoing Phase I/II clinical trial concerning AXL1717

Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA.

Abbott to acquire the global rights to PanGenetics’ new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a [...]

NicOx reports top-line results from first-in-man study of its NO-donating HMG-CoA Reductase Inhibitor

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.